249 related articles for article (PubMed ID: 8612385)
1. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
2. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
4. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
6. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
Cai W; Chen B; Tao X; Ling S; Zhang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
10. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.
Lutz U; Völkel W; Lutz RW; Lutz WK
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):217-25. PubMed ID: 15556536
[TBL] [Abstract][Full Text] [Related]
12. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
[TBL] [Abstract][Full Text] [Related]
13. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity.
Ishiguro A; Kubota T; Ishikawa H; Iga T
Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
15. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
17. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
[TBL] [Abstract][Full Text] [Related]
18. Nicotine metabolism and CYP2D6 phenotype in smokers.
Caporaso NE; Lerman C; Audrain J; Boyd NR; Main D; Issaq HJ; Utermahlan B; Falk RT; Shields P
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):261-3. PubMed ID: 11303596
[TBL] [Abstract][Full Text] [Related]
19. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
Caporaso NE; Shaw GL
Arch Intern Med; 1991 Oct; 151(10):1985-92. PubMed ID: 1681790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
